ArticleMediators of inflammation2026
Evaluating Ribosomal Protein L19 mRNA as a Biomarker in Ulcerative Colitis: Implications for Severity Assessment.
Article in Mediators of inflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evaluating Ribosomal Protein L19 mRNA as a Biomarker in Ulcerative Colitis: Implications for Severity Assessment.Mediators of inflammation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundUlcerative colitis (UC) is a chronic inflammatory disease of the gastrointestinal tract, characterized by immune dysregulation, genetic susceptibility, and environmental factors such as diet and psychosocial stress. The etiology of UC is complex, involving multiple interrelated factors that drive its pathogenesis and clinical progression.
methodsThis cross-sectional study investigated the potential role of ribosomal protein L19 (RPL19) mRNA in UC. A total of 40 patients with UC and 29 healthy controls (HC) were prospectively enrolled from the Department of Gastroenterology, Affiliated Hospital of Jining Medical University, between November 2021 and November 2023. RPL19 mRNA levels in the intestinal mucosa of UC patients were quantified using quantitative PCR analysis. Subsequently, the associations of RPL19 mRNA expression with disease severity and with the levels of key inflammatory cytokines were statistically assessed.
resultsRPL19 mRNA expressions were significantly regulated in UC patients compared to HC. It exhibited a significant inverse correlation with the levels of both interleukin-2 (IL-2) and interleukin-4 (IL-4). Importantly, RPL19 mRNA levels also correlated with key clinical disease activity indices.
conclusionsThis study demonstrates that mucosal RPL19 mRNA expression levels are significantly elevated in UC patients and correlate positively with endoscopic and histological disease severity. These findings identify RPL19 as a potential biomarker for reflecting local disease activity in UC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.